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Purpose of the study
The concomitant use of tenofovir DF (TDF) in combina-
tion with different protease inhibitors (PIs) has been
widely investigated, especially in treatment-naïve
patients. Although some data exist in treatment-experi-
enced patients receiving TDF with the commonly used
PIs, such as atazanavir or lopinavir, data from other
TDF+PI combinations are lacking.
Methods
The PROTECTION cohort included retrospective data
from 1,428 HIV patients treated with different TDF+PI
combinations from 80 HIV clinics in Spain. We have per-
formed a sub-analysis of those patients whose HAART reg-
imens included at TDF in combinations including
saquinavir (SQV) or fosamprenavir (FPV).
Summary of results
Tables 1 and 2.
The most prevalent adverse event was diarrhoea in the
SQV cohort (11%) and hypertrigliceridaemia in the FPV
cohort (4%). Only four patients (2%) withdrew their
treatment due to an adverse event. One patient (0.5%)
with baseline mild renal impairment (GFR: 63 mL/min)
withdrew his treatment due to a grade 1 GFR decrease.
Conclusion
In this cohort, concomitant use of TDF with SQV or FPV
was associated with good tolerability and an adequate rate
of viral effectiveness, suggesting these combinations are
suitable as rescue therapy in highly treatment-experienced
patients.
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Table 1: Baseline characteristics.
FPV Cohort (n = 105) SQV Cohort (n = 98)
% Male 74% 65%
Mean Age (years) 43 41
Primary HIV risk factor (%) IVDU (53%) IVDU (53%)
CDC C status (%) 44% 34%
Main reasons for TDF based regimen (%) Virological failure (59%) Virological failure (48%)
Toxicity management (19%) Simplification (20%)
Previous time on ARV; Months. Median (IQR) 70 (21–111) 73 (34–111)
Most common acompanying NRTIs 3TC or FTC (36%) 3TC or FTC (65%)
AZT or d4T (26%) AZT or d4T (7%)
ddI (11%) ddI (13%)
Median BL HIV RNA, c/mL (log) 3.9 3.3
Mean BL CD4 count (cell/mm3) 335 387
BL = Baseline; ARV = antiretrovirals.
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Table 2: Efficacy outcomes.
FPV Cohort (n = 105) SQV Cohort (n = 98)
% viral failure 22% 13%
Mean time of follow-up (months) 10.5 9.6
Mean CD4 count increase* +84 cells/mm3 +12 cells/mm3
*In those subjects with 48 week data available (n = 36 and 26 for FPV and SQV cohorts, respectively).
